血清趋化因子16表达水平在宫颈癌诊断中的价值

发布时间：2018-04-23 02:17

本文选题：宫颈癌 + 趋化因子　；参考：《现代预防医学》2015年24期

【摘要】：目的探讨血清趋化因子16(CX~CL16)表达水平在宫颈癌诊断中的价值。方法回顾性分析某院就诊的宫颈癌、宫颈上皮内瘤变、宫颈炎患者和健康对照患者其血清CX~CL16和糖蛋白抗原125(CA125)水平,比较其诊断阳性率。结果宫颈癌患者血清CX~CL16、CA125水平明显高于宫颈上皮内瘤变、宫颈炎和健康对照组(F=4.432,P=0.000;F=2.452,P=0.027);宫颈癌晚期患者血清CX~CL16和CA125与宫颈癌早期相比显著升高(t=18.241,12.441;P=0.000,0.000);宫颈癌患者、宫颈上皮内瘤变患者和宫颈炎患者血清CX~CL16水平诊断阳性率分别为91.12%、13.21%和16.44%;血清CA125水平诊断阳性率分别为76.47%、56.60%和50.68%,宫颈癌患者血清CX~CL16水平诊断阳性率与血清CA125水平诊断阳性率相比显著升高(χ~2=5.423,P=0.020),宫颈内上皮瘤变和宫颈炎患者血清CX~CL16水平诊断阳性率与血清CA125水平诊断阳性率相比显著降低(χ~2=17.322,8.916,P=0.000,0.000);宫颈癌早期、晚期血清CX~CL16水平诊断阳性率为88.89%、100.00%,分别显著高于血清CA125水平诊断阳性率69.44%、81.25%(χ~2=4.126,6.621;P=0.042,0.010)。结论血清CX~CL16可以做为一种宫颈癌的肿瘤标志物,较为特异和准确地在临床上应用于宫颈癌的诊断。
[Abstract]:Objective to investigate the value of serum chemokine 16 (CX L 16) expression in the diagnosis of cervical cancer. Methods the serum levels of CX~CL16 and glycoprotein antigen 125 CA125 in patients with cervical cancer, cervical intraepithelial neoplasia, cervicitis and healthy control were analyzed retrospectively and the positive rate of diagnosis was compared. Results the serum levels of CXC16 and CA125 in patients with cervical cancer were significantly higher than those in patients with cervical intraepithelial neoplasia. The levels of serum CX~CL16 and CA125 in patients with advanced cervical cancer were significantly higher than those in the early stage of cervical cancer, and the levels of serum CX~CL16 and CA125 in patients with cervical cancer were significantly higher than those in patients with cervical cancer. The positive rates of serum CX~CL16 level in patients with cervical intraepithelial neoplasia and cervicitis were 91.121.21% and 16.44%, respectively, and the positive rates of serum CA125 levels were 76.470.60% and 50.68%, respectively. The positive rates of serum CX~CL16 levels and serum CA125 levels in cervical cancer patients were 56.60% and 50.68, respectively. The positive rate of serum CX~CL16 in patients with cervical epithelioma and cervicitis was significantly higher than that in serum CA125 (蠂 ~ 2 / 2, 5.423, P ~ (0.020)), and the positive rate of serum CX~CL16 was significantly lower than that of serum CA125 (蠂 ~ (2 / 2) 17.3228.916 ~ (0.000) ~ 0.000 ~ 0.000 ~ 0.000 ~ 0.000 ~ 0.000 ~ 0.000). The positive rate of serum CX~CL16 in late stage was 88.89 and 100.000.It was significantly higher than that of serum CA125 69.44and 81.25, respectively (蠂 ~ (2 / 2) 4.126 ~ 6.621 ~ 0.042 ~ 0.010). Conclusion Serum CX~CL16 can be used as a tumor marker of cervical cancer and can be used in clinical diagnosis of cervical cancer.
【作者单位】：黑龙江省大庆龙南医院妇产科;上海市东方医院妇产科;
【分类号】：R737.33

【相似文献】